GSK gained rights to a Hutchmed antibody-targeted therapy conjugate, or ATTC. This new type of targeted therapy blocks two cancer-driving proteins and will initially be developed for lung, colorectal, and pancreatic cancers.
The post GSK Pays $110M for Phase 1-Ready Hutchmed Asset in a New Class of Cancer Drugs appeared first on MedCity News.
